An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors

References

• Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473(14):2023–2032.
   Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112:4421–4468.
   Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767–777.
   Google Scholar
• De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2013;8:793–810.
   Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88.
   Google Scholar
• Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Discov. 2019;14:1175–1197.
   Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31:345–360.
   Google Scholar
• Berrino E, Supuran CT. Novel approaches for designing drugs that interfere with pH regulation. Expert Opin Drug Discov. 2019;14:231–248.
   Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018;8(2):E25.
   Google Scholar
• De Simone G, Di Fiore A, Capasso C, et al. The zinc coordination pattern in the eta-carbonic anhydrase from Plasmodium falciparum is different from all other carbonic anhydrase genetic families. Bioorg Med Chem Lett. 2015;25:1385–1389.
   Google Scholar
• Kikutani S, Nakajima K, Nagasato C, et al. Thylakoid luminal theta-carbonic anhydrase critical for growth and photosynthesis in the marine diatom Phaeodactylum tricornutum. Proc Natl Acad Sci U S A. 2016;113:9828–9833.
   Google Scholar
• Jensen EL, Clement R, Kosta A, et al. A new widespread subclass of carbonic anhydrase in marine phytoplankton. Isme J. 2019;13:2094–2106.
   Google Scholar
• Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007;13:181–188.
   Google Scholar
• Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013–2019. Expert Opin Ther Pat. 2019;29:781–792.
   Google Scholar
• Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:705–716.
   Google Scholar
• Supuran CT. The management of glaucoma and macular degeneration. Expert Opin Ther Pat. 2019;29:745–747.
   Google Scholar
• Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). Expert Opin Ther Pat. 2013;23:681–691.
   Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:717–724.
   Google Scholar
• Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest. 2008;133:744–755.
   Google Scholar
• Swietach P. What is pH regulation, and why do cancer cells need it? Cancer Metastasis Rev. 2019;38:5–15.
   Google Scholar
• Monti DM, De Simone G, Langella E, et al. Insights into the role of reactive sulfhydryl groups of carbonic anhydrase III and VII during oxidative damage. J Enzyme Inhib Med Chem. 2017;32:5–12.
   Google Scholar
• Datta R, Shah GN, Rubbelke TS, et al. Progressive renal injury from transgenic expression of human carbonic anhydrase IV folding mutants is enhanced by deficiency of p58IPK. Proc Natl Acad Sci U S A. 2010;107:6448–6452.
   Google Scholar
• Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat. 2018;28:713–721.
   Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat. 2013;23:725–735.
   Google Scholar
• Costa G, Carta F, Ambrosio FA, et al. A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors. Eur J Med Chem. 2019;181:111565.
   Google Scholar
• Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem. 2016;31:894–899.
   Google Scholar
• Nishimori I, Minakuchi T, Onishi S, et al. Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J Med Chem. 2007;50:381–388.
   Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother. 2016;16:961–968.
   Google Scholar
• Carta F, Di Cesare Mannelli L, Pinard M, et al. A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. Bioorg Med Chem. 2015;23:1828–1840.
   Google Scholar
• Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev. 2018;38:1799–1836.
   Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27:963–970.
   Google Scholar
• Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018). Expert Opin Ther Pat. 2018;28:729–740.
   Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 2011;54:1896–1902.
   Google Scholar
• Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem. 2016;31(sup4):60–63.
   Google Scholar
• Akgul O, Di Cesare Mannelli L, Vullo D, et al. Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis. J Med Chem. 2018;61:4961–4977.
   Google Scholar
• Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem. 2017;60:1159–1170.
   Google Scholar
• Battke C, Kremmer E, Mysliwietz J, et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother. 2011;60:649–658.
   Google Scholar
• Bernardino RL, Dias TR, Moreira BP, et al. Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human sertoli cells. Febs J. 2019;286:1393–1406.
   Google Scholar
• Supuran CT. Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review. Expert Opin Ther Pat. 2019;29:761–767.
   Google Scholar
• Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother. 2015;15:851–856.
   Google Scholar
• Temperini C, Cecchi A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009;17:1214–1221.
   Google Scholar
• Temperini C, Cecchi A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference. J Med Chem. 2009;52:322–328.
   Google Scholar
• Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12:423–431.
   Google Scholar
• Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47:550–557.
   Google Scholar
• Dogné JM, Supuran C, Pratico D. Adverse cardiovascular effects of the coxibs. J Med Chem. 2005;48:2251–2257.
   Google Scholar
• Anderson CJ, Kaufman PL, Sturm RJ. Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin. Am J Ophthalmol. 1978;86:516–519.
   Google Scholar
• Hazouard E, Grimbert M, Jonville-Berra AP, et al. Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid. J Fr Ophtalmol. 1999;22:73–75.
   Google Scholar
• Cappon GD, Fleeman TL, Cook JC, et al. Combined treatment potentiates the developmental toxicity of ibuprofen and acetazolamide in rats. Drug Chem Toxicol. 2005;28:409–421.
   Google Scholar
• Yablonski ME, Maren TH, Hayashi M, et al. Enhancement of the ocular hypotensive effect of acetazolamide by diflunisal. Am J Ophthalmol. 1988;106:332–336.
   Google Scholar
• Hampson AJ, Babalonis S, Lofwall MR, et al. A pharmacokinetic study examining acetazolamide as a novel adherence marker for clinical trials. J Clin Psychopharmacol. 2016;36:324–332.
   Google Scholar
• Hoff E, Zou D, Schiza S, et al. Carbonic anhydrase, obstructive sleep apnea and hypertension: effects of intervention. J Sleep Res. 2019;e12956. DOI:10.1111/jsr.12956
   Google Scholar
• Angeli A, Supuran CT. Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist: a patent evaluation of CA2958110 and IN6616DEN2012. Expert Opin Ther Pat. 2018;28:723–727.
   Google Scholar
• Terziyski K, Draganova A. Central sleep apnea with cheyne-stokes breathing in heart failure - from research to clinical practice and beyond. Adv Exp Med Biol. 2018;1067:327–351.
   Google Scholar
• Kasap M, Aamodt EJ, Sagrera CE, et al. Novel pharmacological modulation of dystonic phenotypes caused by a gain-of-function mutation in the Na+ leak-current channel. Behav Pharmacol;2020. in press. DOI:10.1097/FBP.0000000000000526
   Google Scholar
• Fossati S, Giannoni P, Solesio ME, et al. The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiol Dis. 2016;86:29–40.
   Google Scholar
• Angiulli F, Solesio ME, Debure L, et al. Carbonic anhydrase inhibitors ameliorate neurovascular dysfunction in a mouse model of cerebral amyloid angiopathy. Alzheimer’s Dement J Alzheimer’s Assoc. 2018;14:P1296.
   Google Scholar
• Provensi G, Carta F, Nocentini A, et al. A new kid on the block? Carbonic anhydrases as possible new targets in Alzheimer’s disease. Int J Mol Sci. 2019;20:E4724.
   Google Scholar
• De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des. 2008;14:655–660.
   Google Scholar
• Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett. 2003;13:841–845.
   Google Scholar
• De Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005;15:2315–2320.
   Google Scholar
• Arechederra RL, Waheed A, Sly WS, et al. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. Bioorg Med Chem. 2013;21:1544–1548.
   Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2012;17:11–15.
   Google Scholar
• Milburn-McNulty P, Powell G, Sills GJ, et al. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2013;3:CD009472.
   Google Scholar
• Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43:763–780.
   Google Scholar
• Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004;13(Suppl 1):S5–9.
   Google Scholar
• Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40:526–548.
   Google Scholar
• Yamamoto Y, Takahashi Y, Imai K, et al. Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19. Epilepsy Behav. 2014;34:124–126.
   Google Scholar
• Schidlitzki A, Bascuñana P, Srivastava PK, et al. Proof-of-concept that network pharmacology is effective to modify development of acquired temporal lobe epilepsy. Neurobiol Dis. 2020;134:104664.
   Google Scholar
• Moseley BD, Otoul C, Staelens L, et al. Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: pooled analysis of data from randomized clinical trials. Epilepsy Res. 2019;158:106218.
   Google Scholar
• Gaston TE, Bebin EM, Cutter GR, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–1592.
   Google Scholar
• Socała K, Wyska E, Szafarz M, et al. Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: pharmacodynamic and pharmacokinetic studies. Neuropharmacology. 2019;158:107733.
   Google Scholar
• Gaston TE, Bebin EM, Cutter GR, et al. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label expanded access program. Epilepsy Behav. 2019;98:201–206.
   Google Scholar
• Temperini C, Innocenti A, Scozzafava A, et al. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem. 2010;53:850–854.
   Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009;131:3057–3062.
   Google Scholar
• Sawicka KM, Florek-Łuszczki M, Wawryniuk A, et al. Dronedarone (a multichannel blocker) enhances the anticonvulsant potency of lamotrigine, but not that of lacosamide, pregabalin and topiramate in the tonic-clonic seizure model in mice. Epilepsy Res. 2019;154:62–68.
   Google Scholar
• Koristkova B, Grundmann M, Brozmanova H, et al. Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes in paediatric patients. Basic Clin Pharmacol Toxicol. 2019;125:26–33.
   Google Scholar
• Asconapé J. Pharmacokinetic considerations with the use of antiepileptic drugs in patients with HIV and organ transplants. Curr Neurol Neurosci Rep. 2018;18:89.
   Google Scholar
• Sawicka KM, Załuska K, Wawryniuk A, et al. Ivabradine attenuates the anticonvulsant potency of lamotrigine, but not that of lacosamide, pregabalin and topiramate in the tonic-clonic seizure model in mice. Epilepsy Res. 2017;133:67–70.
   Google Scholar
• Cortés-Moreno GY, Roa-Coria JE, Zúñiga-Romero Á, et al. Anorectic efficacy and safety of the diethylpropion-topiramate combination in rats. Drug Dev Res. 2018;79:225–233.
   Google Scholar
• van Koert RR, Bauer PR, Schuitema I, et al. Caffeine and seizures: A systematic review and quantitative analysis. Epilepsy Behav. 2018;80:37–47.
   Google Scholar
• Yamamoto Y, Takahashi Y, Imai K, et al. Effect of CYP inducers/inhibitors on topiramate concentration: clinical value of therapeutic drug monitoring. Ther Drug Monit. 2017;39:55–61.
   Google Scholar
• Mutch AM. Recurrent admissions for hypothermia from concomitant topiramate and phenobarbital: a case report. J Pharm Pract. 2019;32:109–112.
   Google Scholar
• Stöllberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98–101.
   Google Scholar
• Galgani A, Palleria C, Iannone LF, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018;9:1067.
   Google Scholar
• Uemura MT, Asano T, Hikawa R, et al. Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. Neurosci Res. 2017;124:25–32.
   Google Scholar
• de Brito AM, de Almeida Pinto MG, Bronstein G, et al. Topiramate combined with cognitive restructuring for the treatment of gambling disorder: a two-center, randomized, double-blind clinical trial. J Gambl Stud. 2017;33:249–263.
   Google Scholar
• Gray JC, Treloar Padovano H, Wemm SE, et al. Predictors of topiramate tolerability in heavy cannabis-using adolescents and young adults: a secondary analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2018;38:134–137.
   Google Scholar
• Owona BA, Zug C, Schluesener HJ, et al. Amelioration of behavioral impairments and neuropathology by antiepileptic drug topiramate in a transgenic Alzheimer’s disease model mice, APP/PS1. Int J Mol Sci. 2019;20:E3003.
   Google Scholar
• Kim HT, Cha H, Hwang KY. Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649). Biochem Biophys Res Commun. 2016;478:1–6.
   Google Scholar
• Werner U, Werner D, Rau T, et al. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74:130–137.
   Google Scholar
• Varma GYN, Kummari G, Paik P, et al. Celecoxib potentiates antibiotic uptake by altering membrane potential and permeability in Staphylococcus aureus. J Antimicrob Chemother. 2019;74:3462–3472.
   Google Scholar
• Mateus PAM, Kido LA, Silva RS, et al. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice. Prostate. 2019;79:515–535.
   Google Scholar
• Angeli F, Trapasso M, Signorotti S, et al. Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. Expert Rev Clin Pharmacol. 2018;11:1073–1084.
   Google Scholar
• Chu TH, Chan HH, Hu TH, et al. Celecoxib enhances the therapeutic efficacy of epirubicin for novikoff hepatoma in rats. Cancer Med. 2018;7:2567–2580.
   Google Scholar
• Kuchuk O, Tuccitto A, Citterio D, et al. pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. Oncoimmunology. 2018;7:e1445452.
   Google Scholar
• Zhang G, Gan YH. Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN. Oncol Rep. 2017 Nov;38(5):2657–2666.
   Google Scholar
• Stazi G, Fioravanti R, Mai A, et al. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Curr Opin Chem Biol. 2019;50:89–100.
   Google Scholar
• Gowda R, Sharma A, Robertson GP. Synergistic inhibitory effects of celecoxib and plumbagin on melanoma tumor growth. Cancer Lett. 2017;385:243–250.
   Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites. 2017;7:E48.
   Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32(44):5210–5219.
   Google Scholar
• McDonald PC, Swayampakula M, Dedhar S. Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites. 2018;8(1):E20.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03450018 (last access on 2020 Jan 29).
   Google Scholar
• Ruzzolini J, Laurenzana A, Andreucci E, et al. A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer. J Enzyme Inhib Med Chem. 2020;35(1):391–397.
   Google Scholar
• Andreucci E, Ruzzolini J, Peppicelli S, et al. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem. 2019;34(1):117–123.
   Google Scholar
• Bryant JL, Gieling RG, Meredith SL, et al. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Int J Cancer. 2018;142:191–201.
   Google Scholar
• Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem. 2016;31(sup1):119–125.
   Google Scholar
• Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites. 2017;8(1):E2.
   Google Scholar
• Boyd NH, Walker K, Fried J, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017;2(24):92928.
   Google Scholar
• McDonald PC, Chafe SC, Brown WS, et al. Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology. 2019;157(3):823–837.
   Google Scholar
• Hedlund EE, McDonald PC, Nemirovsky O, et al. Harnessing induced essentiality: targeting carbonic anhydrase IX and angiogenesis reduces lung metastasis of triple negative breast cancer xenografts. Cancers (Basel). 2019;11:E1002.
   Google Scholar
• Chafe SC, McDonald PC, Saberi S, et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res. 2019;7:1064–1078.
   Google Scholar
• McDonald PC, Chia S, Bedard PL, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol. 2020. in press (accepted for publication).
   Google Scholar
• Alterio V, Kellner M, Esposito D, et al. Biochemical and structural insights into carbonic anhydrase XII/Fab6A10 complex. J Mol Biol. 2019;431:4910–4921.
   Google Scholar
• Nocentini A, Supuran CT. Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013–2019). Expert Opin Ther Pat. 2019;29:805–815.
   Google Scholar
• Angeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013–2018). Expert Opin Ther Pat. 2019;29:793–803.
   Google Scholar